Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11110)	5/8/2017 2:18:32 PM
From: scaram(o)uche	Respond to of 12215

and BTW, Tuck.... kept a small portion of the shares (rxdx). About 10%. (ducking)

To: scaram(o)uche who wrote (11110)	5/8/2017 2:35:06 PM
From: tuck	Read Replies (1) \| Respond to of 12215

RXDX Right, once priced, I tried for $6.35, but it didn't come close. Though patience may yet reward me there. So far, behaving in marked contrast to other recent bio-secondaries. CARA and MGNX come to mind. I got a lucky spike and bailed my CARA trading shares for dinner money, having bought the post announcement pre-pricing weakness. Since then, I've been selling puts on it, and am a bit under water, wondering why it's behaving so much worse than RXDX and MGNX, since all three haven't had other significant news to explain the difference. Cheers, Tuck